December 1, 2016 - By Ruchi Gupta · 0 Comments
The stock of Dexcom Incorporated (NASDAQ:DXCM) registered an increase of 0.85% in short interest. DXCM’s total short interest was 5.52M shares in December as published by FINRA. Its up 0.85% from 5.48 million shares, reported previously. With 684,000 shares average volume, it will take short sellers 8 days to cover their DXCM’s short positions. The short interest to Dexcom Incorporated’s float is 7.13%. About 818,538 shares traded hands. DexCom, Inc. (NASDAQ:DXCM) has declined 1.02% since April 28, 2016 and is downtrending. It has underperformed by 6.94% the S&P500.
Dexcom, Inc. is a medical device company. The company has a market cap of $5.15 billion. The Firm is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. It currently has negative earnings. The Company’s products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.
Insitutional Activity: The institutional sentiment decreased to 1.1 in Q2 2016. Its down 0.25, from 1.35 in 2016Q1. The ratio dropped, as 30 funds sold all DexCom, Inc. shares owned while 77 reduced positions. 46 funds bought stakes while 98 increased positions. They now own 82.43 million shares or 5.55% more from 78.09 million shares in 2016Q1.
Cornerstone Advsrs holds 524 shares or 0.04% of its portfolio. M&T Savings Bank Corp holds 0% or 3,772 shares in its portfolio. Diversified Tru owns 13,488 shares or 0.12% of their US portfolio. Ny State Common Retirement Fund reported 496,476 shares or 0.06% of all its holdings. Utah Retirement last reported 15,000 shares in the company. The Ohio-based Winfield Associates has invested 0% in DexCom, Inc. (NASDAQ:DXCM). Moreover, Ameriprise Financial Inc has 0.18% invested in DexCom, Inc. (NASDAQ:DXCM) for 3.97M shares. Eagle Asset last reported 0.08% of its portfolio in the stock. Honeywell accumulated 0.39% or 191,113 shares. Ibm Retirement Fund holds 0.02% or 8,303 shares in its portfolio. Jennison Associates Ltd Limited Liability Company last reported 1.72M shares in the company. First Mercantile Trust Com last reported 0.17% of its portfolio in the stock. Tocqueville Asset Management Lp last reported 0.02% of its portfolio in the stock. Parametric Portfolio Associates Ltd Liability Co has 94,384 shares for 0.01% of their US portfolio. Savings Bank Of America Corporation De owns 678,889 shares or 0.01% of their US portfolio.
Insider Transactions: Since June 7, 2016, the stock had 0 insider buys, and 63 insider sales for $56.72 million net activity. The insider Pacelli Steven Robert sold $899,473. GREGG TERRANCE H sold 20,000 shares worth $1.82M. DOUBLEDAY RICHARD sold $289,224 worth of DexCom, Inc. (NASDAQ:DXCM) on Tuesday, August 23. On Wednesday, September 7 the insider Balo Andrew K sold $472,156. VALDES JORGE A had sold 32,000 shares worth $2.54M. SKYLER JAY S sold $2.35M worth of DexCom, Inc. (NASDAQ:DXCM) on Friday, September 9. $635,473 worth of DexCom, Inc. (NASDAQ:DXCM) was sold by SAYER KEVIN R on Monday, August 15.
Out of 12 analysts covering Dexcom (NASDAQ:DXCM), 11 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 92% are positive. Dexcom has been the topic of 18 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The rating was maintained by Deutsche Bank with “Buy” on Friday, July 15. The rating was maintained by JP Morgan on Thursday, September 17 with “Overweight”. The firm has “Buy” rating by Piper Jaffray given on Friday, August 7. The firm earned “Neutral” rating on Wednesday, September 14 by BTIG Research. Morgan Stanley initiated the stock with “Overweight” rating in Monday, November 2 report. Benchmark maintained the shares of DXCM in a report on Wednesday, February 24 with “Buy” rating. The stock has “Outperform” rating given by Leerink Swann on Thursday, October 15. The stock has “Buy” rating given by Sterne Agee CRT on Thursday, October 15. The stock has “Neutral” rating given by Robert W. Baird on Monday, February 8. The firm has “Buy” rating given on Wednesday, February 24 by Jefferies.
Dexcom, Inc. (Dexcom), incorporated on May 13, 1999, is a medical device company. The Firm is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. The Company’s products consist of SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile. The Firm had received Conformite Europeene Marking (CE Mark) approval for its fourth generation continuous glucose monitoring system, the DexCom G4 system, enabling commercialization of the DexCom G4 system in the European Union, Australia, New Zealand and the countries in Asia and Latin America.
More recent DexCom, Inc. (NASDAQ:DXCM) news were published by: Fool.com which released: “Here’s Why DexCom, Inc. Is Plunging Today” on November 02, 2016. Also Prnewswire.com published the news titled: “With Health Canada approval, Dexcom G5® Mobile CGM System is the First and …” on November 14, 2016. Prnewswire.com‘s news article titled: “Dexcom and Major League Soccer AT&T Rookie of the Year Jordan Morris Kick-off …” with publication date: November 10, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Ruchi Gupta